Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 5/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092625 | 0.90 | MEN1 (0.39) | MEN1CCR3HRH2HRH1NAMPT | |
| SCHEMBL6623202 | 0.86 | CCR3 (0.42) | MEN1CCR3HRH2HRH1NAMPT | |
| SCHEMBL6741315 | 0.84 | KCNJ1 (0.46) | KDM1ATRPA1 | |
| SCHEMBL5965694 | 0.83 | CCR2 (0.40) | MEN1CCR3HRH2HRH1NAMPT | |
| SCHEMBL6734011 | 0.82 | NAMPT (0.37) | MEN1CCR3HRH2HRH1NAMPT | |
| SCHEMBL6621239 | 0.81 | EPHX2 (0.43) | HRH2HRH1EPHX2 | |
| SCHEMBL6989013 | 0.81 | EPHX2 (0.45) | MEN1CCR3HRH2HRH1KDM1A | |
| SCHEMBL6986200 | 0.80 | CCR3 (0.39) | MEN1CCR3HRH2HRH1EPHX2 | |
| SCHEMBL6097649 | 0.80 | HRH3 (0.39) | MEN1CCR3HRH2HRH1HRH3 | |
| SCHEMBL7035035 | 0.79 | MEN1 (0.39) | MEN1CCR3HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | MEN1 2091/4885CCR3 3995/4885HRH2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.